NewStem
Precision Medicine Therapeutics
Company Overview
Snapshot
Founded in September 2016, NewStem operates with 1–10 employees. The company has raised $5 million across 3 funding rounds from 2 investors. In September 2021, NewStem received investment from Illumina Accelerator Cambridge.
Business overview
NewStem is a Health Tech & Life Sciences company focused on precision medicine therapeutics. The company has developed a novel technology for predicting resistance to anticancer treatments, creating a diagnostic tool based on pioneering research in human haploid pluripotent stem cells (HHPSCs). These cells are utilized for various applications, from basic research to therapeutics, addressing the challenge of tumor resistance to anticancer drugs by enabling the generation of fully functional haploid stem cells with unique genetic makeups. NewStem operates in the diagnostics, personalized medicine, and oncology sectors, serving the healthcare industry.
Strategic signal
In April 2022, NewStem filed an FDA pre-submission and EMA IVDD for a diagnostic device. This move signals the company's progress towards regulatory approval for its technology, which could significantly impact cancer treatment by providing a tool to predict chemotherapy resistance. For investors, this indicates a critical step in commercializing its precision medicine platform and validating its diagnostic capabilities in major markets.
Log in to access full profile ›Company Intelligence Q&A
- What is NewStem's primary focus?
- NewStem focuses on precision medicine therapeutics, developing a novel technology to predict resistance to anticancer treatments using human haploid pluripotent stem cells (HHPSCs).
- When was NewStem founded?
- NewStem was founded in September 2016.
- What was a significant regulatory milestone for NewStem?
- In April 2022, NewStem filed an FDA pre-submission and EMA IVDD for its diagnostic device, indicating progress towards regulatory clearance for its technology.
- Which investor participated in NewStem's September 2021 funding round?
- In September 2021, NewStem received investment from Illumina Accelerator Cambridge.
- What was NewStem's status as of October 2024?
- NewStem ceased to operate in October 2024.